» Articles » PMID: 39035219

Oxalate Regulates Crystal-cell Adhesion and Macrophage Metabolism Via JPT2/PI3K/AKT Signaling to Promote the Progression of Kidney Stones

Overview
Journal J Pharm Anal
Specialty Chemistry
Date 2024 Jul 22
PMID 39035219
Authors
Affiliations
Soon will be listed here.
Abstract

Oxalate is an organic dicarboxylic acid that is a common component of plant foods. The kidneys are essential organs for oxalate excretion, but excessive oxalates may induce kidney stones. Jupiter microtubule associated homolog 2 (JPT2) is a critical molecule in Ca mobilization, and its intrinsic mechanism in oxalate exposure and kidney stones remains unclear. This study aimed to reveal the mechanism of JPT2 in oxalate exposure and kidney stones. Genetic approaches were used to control JPT2 expression in cells and mice, and the JPT2 mechanism of action was analyzed using transcriptomics and untargeted metabolomics. The results showed that oxalate exposure triggered the upregulation of JPT2, which is involved in nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated Ca mobilization. Transcriptomic analysis revealed that cell adhesion and macrophage inflammatory polarization were inhibited by JPT2 knockdown, and these were dominated by phosphatidylinositol 3-kinase (PI3K)/AKT signaling, respectively. Untargeted metabolomics indicated that JPT2 knockdown inhibited the production of succinic acid semialdehyde (SSA) in macrophages. Furthermore, JPT2 deficiency in mice inhibited kidney stones mineralization. In conclusion, this study demonstrates that oxalate exposure facilitates kidney stones by promoting crystal-cell adhesion, and modulating macrophage metabolism and inflammatory polarization via JPT2/PI3K/AKT signaling.

References
1.
Sheng X, Jung T, Wesson J, Ward M . Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci U S A. 2004; 102(2):267-72. PMC: 544292. DOI: 10.1073/pnas.0406835101. View

2.
Morgan M, Pearle M . Medical management of renal stones. BMJ. 2016; 352:i52. DOI: 10.1136/bmj.i52. View

3.
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X . Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1):26. PMC: 6379961. DOI: 10.1186/s12943-019-0954-x. View

4.
Haffner C, Becherer J, Boros E, Cadilla R, Carpenter T, Cowan D . Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors. J Med Chem. 2015; 58(8):3548-71. DOI: 10.1021/jm502009h. View

5.
Witting C, Langman C, Assimos D, Baum M, Kausz A, Milliner D . Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2020; 16(3):487-495. PMC: 8011014. DOI: 10.2215/CJN.08000520. View